Durée du stage: 6 months
Laboratoire d’accueil: AFMB, 163 avenue de Luminy, 13288 – Marseille
Site web : https://www.afmb.univ-mrs.fr/facility/biologie-structurale/production-de-proteines-
recombinantes-en-systemes-eucaryotes/
Contexte :
Marburg virus (MARV) causes severe disease, and its envelope glycoprotein (GP), which mediates viral entry, is a major target for neutralizing antibodies and vaccine development [1–3]. Engineering soluble GP variants that combine efficient expression, stability and native-like antigenicity requires robust production and screening methods. This project will be conducted within the AFMB/PBSIM “Recombinant protein production in eukaryotic cell systems” platform, linking the development of mammalian expression workflows to the evaluation of engineered MARV GP designs.
Objectif du stage :
Profil attendu du candidat:
Master 2 student in molecular biology, biochemistry, structural biology, biotechnology or a related discipline. Basic laboratory experience in cell culture and/or recombinant protein production is desirable; The candidate should be rigorous, organized, motivated to learn new techniques. Modalités des candidatures : Merci de faire parvenir un CV, une lettre de motivation, une lettre de recommandation et les résultats de la licence 3 et du Master 1 (notes et classement), par mail à
yoann.aldon@univ-amu.fr et claire.debarnot@univ-amu.fr
Références bibliographiques :
(1) King LB et al. The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. Cell Host Microbe. 2018;23: 101–109.e4.
(2) Lee Y-Z et al. Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification. Nat Commun. 2025;16: 11368.
(3) Ye G, et al. Structures of Marburgvirus glycoprotein and its complex with NPC1 receptor. Nature. 2026;653: 621–626.
Publié le novembre 18, 2026